Evidence map›Paper›PMID 38474266›Full record

ArticleInternational journal of molecular sciences2024

The Expression and Functionality of CB

Irene Reyes-Resina, Jaume Lillo, Iu Raïch, Joan Biel Rebassa, Gemma Navarro

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. The Interplay Between CBInternational journal of molecular sciences · 2025
    Article
  3. Future Perspectives of NMDAR in CNS Disorders.Molecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Irene Reyes-ResinaDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-2077-2537
Jaume LilloNetwork Center for Biomedical Research in Neurodegenerative Diseases, CiberNed, Spanish National Health Institute Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.
Iu RaïchDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain.
Joan Biel RebassaDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain.
Gemma NavarroDepartment of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-4654-0873
Biomedical Research Networking Center on Neurodegenerative Diseases · ES

Funding

Spanish Ministry of Science and Innovation PID 2020-113430RB-I00Spanish Ministry of Science and Innovation PID 2021-126600OB-I00
6 · The paper itself

Abstract

One of the hallmarks of Parkinson's disease (PD) is the alteration in the expression and function of NMDA receptor (NMDAR) and cannabinoid receptor 1 (CB

Indexed as

Parkinson Diseasealpha-SynucleinAnimalsMiceNerve Tissue ProteinsNeuronsReceptor, Cannabinoid, CB1Receptors, N-Methyl-D-AspartateSignal Transductionalpha-SynucleinCNR1 protein, mouseGprin1 protein, mouseNerve Tissue ProteinsReceptor, Cannabinoid, CB1Receptors, N-Methyl-D-Aspartatecannabinoid receptor 1NMDA receptorParkinson’s diseasereceptor heteromerα-synuclein

Identifiers

PMID38474266
PMCPMC10931566
OpenAlexW4392455296

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.